ResearchMoz

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies

GBI Research
Published Date » 2013-12-03
No. Of Pages » N/A
   
 GBI Research has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications....
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 5
2.1 Ophthalmology Therapeutics in Major Markets is Expected to Reach $6.1 Billion by 2019, with Growth of 7.6% 5
2.2 Moderate Pipeline with Promising Drugs in Late Stages of Development could Drive Market Expectations 7

3 Ophthalmology Therapeutics in Major Markets – Introduction 9
3.1 Dry Eye Syndrome 9
3.1.1 Classification 9
3.1.2 Symptoms 9
3.1.3 Etiology 9
3.1.4 Pathophysiology 10
3.1.5 Diagnosis 11
3.1.6 Epidemiology 12
3.1.7 Prognosis 13
3.1.8 Treatment Options 13
3.2 Glaucoma 14
3.2.1 Classification 14
3.2.2 Symptoms 15
3.2.3 Etiology 15
3.2.4 Pathophysiology 16
3.2.5 Diagnosis 16
3.2.6 Epidemiology 17
3.2.7 Prognosis 18
3.2.8 Treatment Options 18
3.3 GBI Research Report Guidance 19

4 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 19
4.1 Dry Eye Syndrome 19
4.2 Glaucoma 20
4.3 Key Marketed Products 21
4.3.1 Restasis 21
4.3.2 Systane 22
4.3.3 Diquas 23
4.3.4 Mucosta 24
4.3.5 Hyalein 25
4.3.6 Lumigan 26
4.3.7 Alphagan/Alphagan P 27
4.3.8 Simbrinza 28

5 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 28
5.1 Dry Eye Syndrome Pipeline 28
5.1.1 Overall Pipeline 28
5.1.2 Pipeline Analysis by Molecule Type 31
5.1.3 Pipeline Analysis by Mechanism of Action 33
5.2 Glaucoma Pipeline 35
5.2.1 Overall Pipeline 35
5.2.2 Pipeline Analysis by Molecule Type 37
5.2.3 Pipeline Analysis by Mechanism of Action 39
5.3 Promising Drug Candidates in the Pipeline 41
5.3.1 CF-101 41
5.3.2 MIM-D3 41
5.3.3 SAR-1118 41
5.3.4 DE-111 42

6 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 42
6.1 Major Markets 42
6.1.1 Treatment Usage Patterns 42
6.1.2 Annual Cost of Therapy 42
6.1.3 Market Size 42
6.2 The US 44
6.2.1 Treatment Usage Patterns 44
6.2.2 Annual Cost of Therapy 44
6.2.3 Market Size 44
6.3 Top Five European Countries 46
6.3.1 Treatment Usage Patterns 46
6.3.2 Annual Cost of Therapy 46
6.3.3 Market Size 46
6.4 Canada 48
6.4.1 Treatment Usage Patterns 48
6.4.2 Annual Cost of Therapy 48
6.4.3 Market Size 48
6.5 Japan 50
6.5.1 Treatment Usage Patterns 50
6.5.2 Annual Cost of Therapy 50
6.5.3 Market Size 50
6.6 Drivers and Barriers 52
6.6.1 Drivers 52
6.6.2 Barriers 52

7 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 53
7.1 Deals Analysis 53
7.2 Major Co-Development Deals 55
7.2.1 NicOx Signs Research Agreement with Pfizer 56
7.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 56
7.2.3 Akorn Enters into Agreement with Azad Pharma 56
7.3 Major Licensing Deals 57
7.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 58
7.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 58
7.3.3 Asterand Enters into Licensing Agreement with Allergan 58

8 Ophthalmology Therapeutics in Major Markets – Appendix 58
8.1 All Pipeline Drugs by Phase 58
8.1.1 Discovery 58
8.1.2 Preclinical 59
8.1.3 IND/CTA-filed 60
8.1.4 Phase I 60
8.1.5 Phase II 62
8.1.6 Phase III 63
8.1.7 Pre-registration 63
8.1.8 Undisclosed 64
8.2 Market Forecasts to 2019 64
8.2.1 Major Markets 64
8.2.2 The US 65
8.2.3 The UK 65
8.2.4 France 66
8.2.5 Germany 67
8.2.6 Italy 67
8.2.7 Spain 68
8.2.8 Canada 69
8.2.9 Japan 69
8.3 Market Definitions 70
8.4 Abbreviations 70
8.5 Sources 72
8.6 Research Methodology 73
8.6.1 Coverage 74
8.6.2 Secondary Research 74
8.6.3 Primary Research 74
8.6.4 Therapeutic Landscape 75
8.6.5 Geographical Landscape 78
8.6.6 Pipeline Analysis 78
8.7 Expert Panel Validation 78
8.8 Contact Us 78
8.9 Disclaimer 78

List of Tables


Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 13
Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 14
Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 18
Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 58
Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 59
Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 60
Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 60
Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 62
Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 63
Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 63
Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 64
Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012–2019 64
Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012–2019 64
Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012–2019 65
Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012–2019 66
Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012–2019 66
Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012–2019 66
Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012–2019 67
Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012–2019 68
Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012–2019 68
Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012–2019 68
Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012–2019 69
Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 70

List of Figures


Figure 1: Ophthalmology Therapeutics Market, Major Markets, Market Size (bn), 2012–2019 6
Figure 2: Ophthalmology Therapeutics Market, Global, Pipeline by Stage (%), 2013 8
Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 21
Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 23
Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 24
Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 25
Figure 7: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 26
Figure 8: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 27
Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 29
Figure 10: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 32
Figure 11: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 34
Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 36
Figure 13: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 38
Figure 14: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 40
Figure 15: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012–2019 43
Figure 16: Ophthalmology Therapeutics Market, The US, Market Size, 2012–2019 45
Figure 17: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012–2019 47
Figure 18: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012–2019 49
Figure 19: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 51
Figure 20: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 54
Figure 21: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 55
Figure 22: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 57
Figure 23: GBI Research Market Forecasting Model 77

Upcoming Reports:

Industrial Phenols Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Phenol, also known as carbolic acid, is a white crystalline organic compound which is volatile in nature. It is an important industrial commodity as its derivatives are key ingredients in making a wide range of industry products. Phenol and its derivatives are mostly used to make polycarbonates, epoxy resins, Bakelite, nylon, phenolic resins, detergents, herbicides, and pharmaceutical drugs. Its major use that comprises two-third of its production involves the conversion of its derivatives to plastic. The main chemical derivative and the largest market for phenol is bisphenol-A (BPA)....
Welding Products Market - Global Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Welding is a fabrication process particularly used in metal processing and has a wide range of applications from small to large industries. Compared to all other metal joining methods, this method is found to be the most economical and effective as well. This is the only method that can be used in space and in underwater and air. The global market for welding is expected to grow at a substantial rate through 2018 and is estimated to cross USD 22 billion by 2018. Gas and consumable equipment are together dominating the current welding market and account for more that 60% of the...
Nylon 66 Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Nylon 66 is a derivative of nylon synthesized by polycondensation of hexamethyelenediamine and adipic acid. It has superior mechanical properties and high heat resistance as compared to nylon 6. Nylon 66 can be reinforced with fillers, impact modifiers, fibers and internal lubricants to improve its physical properties such as strength, stiffness, ductility, friction properties and wear resistance. Nylon 66 is used for electro-insulating material, various machine parts, ball bearing cages, pipes, airbags, tires, ropes, conveyor belts, carpets fibers and apparel. End user industries of nylon...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...